Metoclopramide News and Research

RSS

High prevalence of galactagogue use among breastfeeding mothers in U.S.

Researchers describe the prevalence of galactagogue use among breastfeeding mothers in the United States and their perceived effects on milk production.

29 May 2023

Magnetic stimulation therapy can help reduce the debilitating symptoms of diabetic gastroparesis

Magnetic stimulation of a group of nerves key to how our gut and brain communicate may help correct the conversation that goes awry in painful, debilitating diabetic gastroparesis, researchers say.

16 May 2023

Antidopaminergic antiemetics associated with elevated risk of ischemic stroke

Drugs known as antidopaminergic antiemetics (ADAs) that are widely used to relieve nausea and vomiting caused, for instance, by migraine, chemotherapy or radiotherapy, and after surgery are associated with an increased risk of ischaemic stroke, finds a study published by The BMJ today.

24 Mar 2022

Anti-emetic drug offers a promising approach to treat chronic myeloid leukemia

Chronic myeloid leukemia (CML) results from a degeneration of the hematopoietic stem cells (leukemia stem cells), thereby leading to the uncontrolled formation of specific white blood cells, the so-called granulocytes.

26 Jan 2021

Severe vomiting in early pregnancy linked to increased autism risk

A new study published in the American Journal of Perinatology shows a 53% increased risk of autism spectrum disorder in children born to women who had excessively severe nausea and vomiting in pregnancy.

3 Oct 2019

MII-pH can help doctors confirm diagnosis of GERD in newborns before treatment

Millions of Americans currently use medication for their indigestion and reflux, so it may come as no surprise that parents and doctors also prescribe medicine for newborns with reflux. However, according to a new study, newborns are likely being over treated the majority of the time with interventions - including surgery - that have risks for the infant.

3 May 2016

Pregnant women with acute migraine more likely to experience adverse birth outcomes

Women who have acute migraine attacks that are severe enough to prompt them to seek care may be more likely to have complications when giving birth, including preterm delivery, preeclampsia and low birthweight. Women 35 and older were seven times more likely to have these complications.

4 Mar 2016

Altos Therapeutics announces issuance of Mexican patent covering dopamine D2/D3 drug candidates

Altos Therapeutics, LLC announced today that the Mexican Institute of Industrial Property has issued Patent Number 323020 titled, "D2 Antagonists, Methods of Synthesis and Methods of Use". The patent broadly and specifically covers the company's dopamine D2/D3 drug candidates, their pharmaceutical compositions, and their use to treat a number of important gastrointestinal conditions in humans, such as gastroparesis.

12 Jan 2015

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.

8 Jan 2015

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

9 May 2014

Parkinson’s patients encouraged to order new Parkinson’s Passport to avoid medicine problems

This World Parkinson’s Day (11 April 2014) Parkinson’s Australia and NPS MedicineWise are encouraging anyone with Parkinson’s — or people caring for someone with the condition — to order a new Parkinson’s Passport to help avoid medicine problems.

9 Apr 2014

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.

16 Mar 2014

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Pregnant women exposed to metoclopramide experience no increased risk of congenital malformations

In an analysis that included more than 40,000 women exposed to the nausea medication metoclopramide in pregnancy, use of this drug was not associated with significantly increased risk of major congenital malformations overall, spontaneous abortion, and stillbirth, according to a study in the October 16 issue of JAMA.

16 Oct 2013

New endoscopic technique reduces symptoms in gastroparesis patients

Physicians at Johns Hopkins say they are encouraged by early results in three patients of their new treatment for gastroparesis, a condition marked by the failure of the stomach to properly empty its contents into the small intestine.

5 Jul 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

FTC votes to approve Watson's acquisition of Actavis

Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies.

16 Oct 2012

Alfa Wassermann, Salix enter license agreement for EIR formulation of rifaximin

Salix Pharmaceuticals, Ltd. and Alfa Wassermann S.p.A. today announced that they have entered into an exclusive agreement by which Salix has licensed rights in the United States and Canada to an extended intestinal release (EIR) formulation of rifaximin for gastrointestinal and respiratory indications, including Crohn's disease.

9 Aug 2012